IP Library Granted Patent US 7,754,728
Granted Patent B2
US 7,754,728 · App. 10/528,343 · Granted Jul 13, 2010

Adenine compound and use thereof

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,754,728
App. No.
10/528,343
Granted
Jul 13, 2010
Kind
B2
Abstract

A drug for topically administration which is effective as an antiallergic agent. The drug for topically administration contains as an active ingredient an adenine compound represented by the general formula (1): [wherein ring A represents a 6 to 10 membered, mono or bicyclic, aromatic hydrocarbon or a 5 to 10 membered, mono or bicyclic, aromatic heterocycle containing one to three heteroatoms selected among 0 to 2 nitrogen atoms, 0 or 1 oxygen atom, and 0 or 1 sulfur atom; n is an integer of 0 to 2; m is an integer of 0 to 2; R represents halogeno, (un)substituted alkyl, etc.; X 1 represents oxygen, sulfur, NR 1 (R 1 represents hydrogen or alkyl), or a single bond; Y 1 represents a single bond, alkylene, etc.; Y 2 represents a single bond, alkylene, etc.; Z represents alkylene; and at least one of Q 1 and Q 2 represents —COOR 10 (wherein R 10 represents (un)substituted alkyl, etc.), etc.] or a pharmaceutically acceptable salt of the compound.

Claims (41)

1. An adenine compound represented by a general formula (1):

wherein

Ring A is a 5 to 10 membered mono or bicyclic heteroaromatic ring containing 1 to 3 heteroatoms selected from the group consisting of 0 to 2 nitrogen atoms, 0 or 1 oxygen atom, and 0 or 1 sulfur atom,

n is an integer selected from 0 to 2, in is an integer selected from 0 or 1,

R is halogen atom, substituted or unsubstituted alkyl group, substituted or unsubstituted cycloalkyl group, substituted or unsubstituted alkoxy group, or substituted or unsubstituted amino group, and when n is 2, R(s) may be the same or different,

X 1 is oxygen atom, sulfur atom, NR 1 (wherein R 1 is hydrogen atom or alkyl group) or a single bond,

Y 1 is a single bond, or alkylene which may be substituted by oxo group,

Y 2 is a single bond, or alkylene,

Z is methylene,

Q 1 is hydrogen atom, halogen atom, hydroxy group, alkoxy group, or a group selected from the group consisting of Substituents set forth below,

Q 2 is a group selected from the group consisting of Substituents set forth below,

when m is 0, Q 1 is a group selected from the group consisting of Substituents set forth below,

Substituents: —COOR 10 ; —COSR 10 ;

wherein R 10 is substituted or unsubstituted alkyl group, substituted or unsubstituted cycloalkyl group, substituted or unsubstituted alkenyl group, substituted or unsubstituted cycloalkenyl group, or substituted or unsubstituted alkynyl group,

its tautomer or its pharmaceutically acceptable salt.

2. The adenine compound according to claim 1 , wherein in the general formula (1), the substituent(s), by which alkyl group, alkenyl group or alkynyl group in R 10 is substituted, are the same or different and at least one substituent selected from the group consisting of halogen atom, hydroxy group, substituted or unsubstituted alkoxy group, substituted or unsubstituted amino group, substituted or unsubstituted aryl group, and substituted or unsubstituted heterocyclic group.

3. The adenine compound according to claim 1 , wherein in the general formula (1), Ring A is pyridine.

4. The adenine compound according to claim 1 , wherein in the general formula (1), Y 1 is C 1-5 alkylene, Q 1 is hydrogen atom, hydroxy group or alkoxy group, Y 2 is a single bond, and Q 2 is —COOR 10 .

5. The adenine compound according to claim 1 , wherein in the general formula (1), R 10 is alkyl group substituted by hydroxy group, amino group, alkylamino group or dialkylamino group, and m is 1.

6. The adenine compound according to claim 1 , wherein in the general formula (1), Y 1 is C 1-5 alkylene, Q 1 is hydrogen atom, hydroxy group or alkoxy group, Y 2 is C 1-3 alkylene, Q 2 is —COOR 10 , and m is 1.

7. The adenine compound according to claim 1 , wherein in the general formula (1), m is 0, Y 1 is C 1-6 alkylene which may be substituted with oxo group, and Q 1 is —COOR 10 .

8. The adenine compound according to claim 1 , wherein in the general formula (1), and X 1 is oxygen atom, sulfur atom or NR 1 (wherein R 1 is hydrogen atom or alkyl group).

9. The adenine compound according to claim 1 , wherein in the general formula (1), m is 0, X 1 is a single bond, Y 1 is C 1-4 alkylene which may be substituted by oxo group, and Q 1 is —COOR 10 .

10. The adenine compound according to claim 1 , wherein in the general formula (1), either 1) or 2) below obtains:

1) n is 0;

2) n is 1 or 2, and R is alkyl group, alkoxy group or halogen atom.

11. A compound selected from the group consisting of:

8-Hydroxy-2-methoxycarbonylmethylamino-9-{(6-methyl-3-pyridyl)methyl}adenine,

2-{2-(Methoxycarbonyloxy)ethoxy}-8-hydroxy-9-{(6-methyl-3-pyridyl)methyl}adenine,

8-Hydroxy-2-methoxycarbonylethyl-9-{(6-methyl-3-pyridyl)methyl}adenine,

2-Butoxy-8-hydroxy-9-(5-methoxycarbonylfurfuryl)adenine,

2-Butoxy-8-hydroxy-9-(5-isopropoxycarbonylfurfuryl)adenine,

2-Butoxy-8-hydroxy-9-{(6-methoxycarbonyl-3-pyridyl)methyl}adenine,

2-Butoxy-8-hydroxy-9-{(6-isopropoxycarbonyl-3-pyridyl)methyl}adenine,

2-Butylamino-8-hydroxy-9-(5-ethoxycarbonylfurfuryl)adenine,

2-Butoxy-8-hydroxy-9-(5-methoxycarbonylmethylfurfuryl)adenine,

2-Butoxy-8-hydroxy-9-{(6-S-methylthiocarbonyl-3-pyridyl)methyl}adenine,

2-Butoxy-8-hydroxy-9-{(6-methoxycarbonylmethyl-3-pyridyl)methyl}adenine,

2-Butoxy-8-hydroxy-9-{(2-methoxycarbonyl-4-pyridyl)methyl}adenine,

2-Butoxy-8-hydroxy-9-{(5-methoxycarbonyl-2-thienyl)methyl}adenine, and

2-Butoxy-8-hydroxy-9-{(5-methoxycarbonylmethyl-3-pyridyl)methyl}adenine.

Assignments (2)
MERGER Recorded Dec 16, 2005
From: SUMITOMO PHARMACEUTICALS COMPANY, LTD.
To: DAINIPPON SUMITOMO PHARMA CO., LTD.
Reel/Frame 017089/0420 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 18, 2005
From: ISOBE, YOSHIAKI; TAKAKU, HARUO; OGITA, HARUSHISA; TOBE, MASANORI; KURIMOTO, AYUMU; OGINO, TETSUHIRO; FUJITA, HITOSHI
To: SUMITOMO PHARMACEUTICALS COMPANY LIMITED
Reel/Frame 017237/0461 →